Alcoholic (ALD) and non-alcoholic fatty liver diseases (NAFLD) are clinical conditions
leading to hepatocellular injury and inflammation resulting from alcohol consumption, high …

Due to the worldwide surge in obesity and type 2 diabetes, the increased incidence of
nonalcoholic fatty liver disease (NAFLD) is a major concern for the public health. Indeed …

Drug-drug interactions (DDIs) arising from the perturbation of drug metabolising enzyme
activities represent both a clinical problem and a potential economic loss for the …

The ontogeny of hepatic uridine diphosphate‐glucuronosyltransferases (UGTs) was
investigated by determining their protein abundance in human liver microsomes isolated …

Drug-metabolizing enzymes play a vital role in the elimination of the majority of therapeutic
drugs. The major organ involved in drug metabolism is the liver. Chronic liver diseases have …

UDP-glucuronosyltransferases (UGTs) are the primary phase II enzymes catalyzing the
conjugation of glucuronic acid to the xenobiotics with polar groups for facilitating their …

The potential toxicity of perfluorooctane sulfonate (PFOS), an environmentally persistent
organic pollutant, is of great concern. The present study examines the ability of PFOS to …

Steatosis, or excessive accumulation of lipids in the liver, is a generally accepted previous
step to the development of more severe conditions like nonalcoholic steatohepatitis, fibrosis …

The constitutive androstane receptor (CAR, NR1I3) plays a crucial role in the regulation of
drug metabolism, energy homeostasis, and cancer development through modulating the …

The brominated flame retardant (BFR) hexabromocyclododecane was tested in a one-
generation reproduction assay in Wistar rats, enhanced for endocrine parameters. A solution …